Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 5% in the afternoon trading session, with a current price of 52.55 HKD and a trading volume of 32.73 million HKD. The company has entered into a memorandum of understanding with Yunnan Watson Bio (300142) to establish a strategic partnership focused on RNA-based preventive and precision medicine [1]. Group 1 - The memorandum of understanding is set for a duration of two years from the date of signing [1]. - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1]. - The partnership will integrate MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and robust clinical pipeline [1]. Group 2 - The strategic partnership will encompass joint development, clinical trials, registration, as well as sales and distribution [1]. - The collaboration is expected to establish a comprehensive platform for research and commercial deployment in preventive and precision medicine [1]. - The partnership will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1].

Core Viewpoint - MIRXES-B (02629) has entered into a memorandum of understanding with Yunnan Watson Biotechnology to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to create synergies [1] Group 2: Technological and Operational Synergies - The partnership will combine MIRXES's advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's proprietary mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Objectives - The partnership will create synergies by combining MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Implications - This partnership signifies a significant transformation for the company, moving from early detection to prevention and precision medicine [1] - The collaboration is expected to create synergies by combining the company's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] Group 3: Operational Capabilities - The partnership will utilize the company's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1] - The collaboration will also enhance distribution channels within ASEAN, integrating research and commercial deployment into a cohesive prevention and precision medicine platform [1]

Core Viewpoint - The company has entered into a memorandum of understanding with Watson Bio-Tech to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1][2] Group 1: Partnership Details - The memorandum outlines collaboration in establishing an RNA-centered research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology to advance RNA-based diagnostic products, vaccines, and therapeutics [1] - The partnership aims to accelerate clinical trials and regulatory approvals for existing and pipeline products in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve the ASEAN region and specific international markets for existing and pipeline products [1] - A supply chain will be established in Singapore to coordinate end production, quality, and commercial deployment of existing and pipeline products [1] Group 2: Strategic Value - The partnership is expected to generate significant strategic value, reinforcing the company's position as a pillar in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - It will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform will facilitate collaboration with global institutions to seize and expand regional opportunities [2] - The collaboration is anticipated to promote cross-border joint investment and cooperation opportunities, enhance corporate visibility, deepen R&D capabilities, and contribute to the long-term development and revenue diversification of the group [2]

Core Insights - The company has signed a memorandum of understanding with Yunnan Watson Bio-Technology Co., Ltd. to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform [1][2] - The memorandum outlines a two-year collaboration period and includes joint development, clinical trials, registration, and sales and distribution [1] Group 1 - The partnership aims to leverage complementary strengths to enhance the company's position in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - The collaboration will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform is expected to facilitate cross-border investment opportunities, enhance corporate visibility, and deepen research and development capabilities [2] Group 2 - The partnership will establish an RNA-focused research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology [1] - Clinical trials and regulatory approvals for existing and pipeline products will be expedited in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve ASEAN and specific international markets [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） 自願性公告 與沃森的諒解備忘錄 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 – 1 – 諒解備忘錄 進行諒解備忘錄項下合作的理由及裨益 本公司董事（「董事」）會（「董事會」）宣佈，本公司近期與雲南沃森生物技術股 份有限公司（「沃森」）訂立了一份諒解備忘錄（「諒解備忘錄」），據此，訂約方已 同意發揮各自的互補優勢，就創建以RNA為中心的預防及精準醫療平台建立戰 略合作夥伴關係，並涵蓋共同開發、臨床試驗及註冊以及銷售及分銷。諒解備 忘錄的期限自簽署日期（包括該日）起為期兩年。 有關沃森的資料 沃森成立於2001年，是中國領先的高科技生物製藥 ...

非執行董事 朱興奮博士 （主席） 樂貝林博士 柳達先生 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 董事名單與其角色及職能 Mirxes Holding Company Limited（「本公司」）董事會（「董事會」）成員載列如下： 執行董事 周礪寒博士 （首席執行官） 鄒瑞陽博士 Mirxes Holding Company Limited 獨立非執行董事 林倩麗博士（別名：TSUI Sin Lai Judy） 方曉先生 馬露玲女士 M 相關董事委員會的成員 香港 2025年11月13日 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 周礪寒博士 | | | M | | 鄒瑞陽博士 | | | | | 朱興奮博士 | M | | | | 樂貝林博士 | | | | | 柳達先生 | | | | | 林倩麗博士 （別名：TSUI Sin Lai Judy） | C | M | | | 方曉先生 | M | C | M | | 馬露玲女士 | | M | C | 附註： C 相關董事委員會的主席 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 延長基石投資者禁售期限制 及 執行董事變更 延長基石投資者禁售期限制 茲提述(i) Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）日期為2025年5月15日之招股章程（「招股章程」）及(ii)本公司日期為2025 年5月22日之配發結果公告（「公告」），內容有關（其中包括）北京潯瑞企業管理 合夥企業（有限合夥）所持合共16,649,200股本公司股份及Evergreen Gate Limited 所持合共2,637,200股本公司股份（統稱「相關股份」）各自的禁售承諾（統稱「禁售 承諾」），二者均為本公司基石投資者（「基石投資者」）。除非另有界定，否則本 公告所用詞彙應與招股章程及公告所界定者 ...

Core Viewpoint - MIRXES-B (02629) has been officially included in the Hang Seng Composite Index and Hong Kong Stock Connect as of September 8, 2025, which is expected to attract significant southbound capital attention and allocation, providing additional upward momentum for the company's stock price [1] Group 1: Market Position and Product Advantage - The company is a global pioneer in gastric cancer early screening, possessing first-mover advantages and technological barriers [1] - The core product GASTROClear is the world's first and only approved molecular diagnostic IVD product for gastric cancer screening, having achieved commercialization in markets such as Singapore and Thailand, and received "breakthrough medical device" designation from the US FDA [1] - The company has over ten years of R&D accumulation in miRNA technology and a strong patent portfolio, including 27 approved patents and 63 pending patent applications, positioning it favorably in the non-invasive cancer early screening market, particularly in Asia where gastric cancer is prevalent [1] Group 2: Revenue Growth and Financial Performance - The company expects revenues for 2025, 2026, and 2027 to be $0.27 billion, $0.41 billion, and $0.75 billion, respectively, with year-on-year growth rates of 30.84%, 55.14%, and 81.32% [1] - In the first half of 2025, the revenue from the "early detection and precision multi-omics" division increased by 50% year-on-year to $10.5 million, driven primarily by GASTROClear and LUNGClear [1] Group 3: Product Pipeline and Future Growth - The company has a clear product pipeline supported by its mature miRNART-qPCR technology platform, with ongoing development of screening products for colorectal cancer (CRC-1), liver cancer (LV-1), and breast cancer (BC-1), as well as a multi-cancer screening project (CADENCE) [2] - LUNGClear has been commercialized as an LDT service in Southeast Asia and Japan, while CRC-1 is expected to complete prototype design and initiate commercialization in Southeast Asia by the second half of 2025 [2] - The pipeline for liver cancer (LV-1) and breast cancer (BC-1) is in early development stages, and the CADENCE project has initiated large-scale clinical research, providing long-term growth potential for the company [2] Group 4: Integrated Industry Capability - The company has established an integrated platform covering R&D, production, and commercialization, creating high barriers and cost advantages [3] - With two cGMP-compliant production facilities in Singapore and China, the company has an annual total capacity of approximately 590,000 tests, ensuring product quality and stable supply while effectively controlling costs [3] - The gross margin for the first half of 2025 increased by 18.8 percentage points to 67.8%, laying a solid foundation for future market competition and profit release [3]